A company that’s developing nutritional supplements tailored to people with heart disease and heart failure has raised more than $1 million in equity.
Dayton, Ohio-area Corceuticals’ funding was sourced from 34 investors, according to a regulatory document.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Corceuticals says its CardiaMin supplement “provides a carefully selected blend of vitamins and minerals while avoiding those which can be harmful or counteract medications commonly used by people with heart disease or heart failure.”
A 30-day supply of the vitamin costs $22.
Corceuticals is a subsidiary of Nephroceuticals, which develops vitamins for people with chronic kidney disease.
A company representative didn’t return a call.